BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S. 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011;12:251-265. [PMID: 21332317 DOI: 10.2217/pgs.10.167] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Lunenburg CA, Henricks LM, Guchelaar H, Swen JJ, Deenen MJ, Schellens JH, Gelderblom H. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. European Journal of Cancer 2016;54:40-8. [DOI: 10.1016/j.ejca.2015.11.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
2 Xu Y, Zhang C, Liang H, Hu S, Li P, Liu L, Duan X, Chen C, Zhang Y, Dai P. Dishevelled 1, a pivotal positive regulator of the Wnt signalling pathway, mediates 5-fluorouracil resistance in HepG2 cells. Artificial Cells, Nanomedicine, and Biotechnology 2018;46:192-200. [DOI: 10.1080/21691401.2018.1453827] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
3 Durinikova E, Plava J, Tyciakova S, Skvara P, Vojs Stanova A, Kozovska Z, Kucerova L, Matuskova M. Cytotoxic response of 5-fluorouracil-resistant cells to gene- and cell-directed enzyme/prodrug treatment. Cancer Gene Ther 2018;25:285-99. [DOI: 10.1038/s41417-018-0030-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Hedbrant A, Erlandsson A, Delbro D, Wijkander J. Conditioned media from human macrophages of M1 phenotype attenuate the cytotoxic effect of 5‑fluorouracil on the HT‑29 colon cancer cell line. Int J Oncol 2015;46:37-46. [PMID: 25310018 DOI: 10.3892/ijo.2014.2696] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013;85:1219-1226. [PMID: 23435357 DOI: 10.1016/j.bcp.2013.02.017] [Cited by in Crossref: 217] [Cited by in F6Publishing: 197] [Article Influence: 24.1] [Reference Citation Analysis]
6 Jennings BA, Loke YK, Skinner J, Keane M, Chu GS, Turner R, Epurescu D, Barrett A, Willis G. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One 2013;8:e78053. [PMID: 24167597 DOI: 10.1371/journal.pone.0078053] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
7 Pagliara V, Saide A, Mitidieri E, d'Emmanuele di Villa Bianca R, Sorrentino R, Russo G, Russo A. 5-FU targets rpL3 to induce mitochondrial apoptosis via cystathionine-β-synthase in colon cancer cells lacking p53. Oncotarget 2016;7:50333-48. [PMID: 27385096 DOI: 10.18632/oncotarget.10385] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 12.3] [Reference Citation Analysis]
8 Ghafouri-Fard S, Abak A, Tondro Anamag F, Shoorei H, Fattahi F, Javadinia SA, Basiri A, Taheri M. 5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent. Front Oncol 2021;11:658636. [PMID: 33954114 DOI: 10.3389/fonc.2021.658636] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Gichumbi JM, Friedrich HB, Omondi B, Singh M, Naicker K, Chenia HY. Synthesis, characterization, and cytotoxic and antimicrobial activities of ruthenium(II) arene complexes with N , N -bidentate ligands. Journal of Coordination Chemistry 2016;69:3531-44. [DOI: 10.1080/00958972.2016.1243238] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
10 Chen Y, Wu J, Cheng K, Li ZP, Luo DY, Qiu M, Gou HF, Yi C, Li Q, Wang X, Yang Y, Cao D, Shen YL, Bi F, Liu JY. S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial. Oncologist 2019;24:591-e165. [PMID: 30651398 DOI: 10.1634/theoncologist.2018-0901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Skvara P, Durinikova E, Grabicová K, Mordacikova E, Matuskova M, Vojs Stanova A. Development of LC-HRMS methods for evaluation of metabolic conversion of 5-fluorocytosine at GDEPT procedure. J Pharm Biomed Anal 2021;203:114168. [PMID: 34089981 DOI: 10.1016/j.jpba.2021.114168] [Reference Citation Analysis]
12 Smyth EC, Cunningham D. Operable gastro-oesophageal junctional adenocarcinoma: Where to next? World J Gastrointest Oncol 2014; 6(6): 145-155 [PMID: 24936225 DOI: 10.4251/wjgo.v6.i6.145] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Hariprakash JM, Vellarikkal SK, Keechilat P, Verma A, Jayarajan R, Dixit V, Ravi R, Senthivel V, Kumar A, Sehgal P, Sonakar AK, Ambawat S, Giri AK, Philip A, Sivadas A, Faruq M, Bharadwaj D, Sivasubbu S, Scaria V. Pharmacogenetic landscape of DPYD variants in south Asian populations by integration of genome-scale data. Pharmacogenomics 2018;19:227-41. [PMID: 29239269 DOI: 10.2217/pgs-2017-0101] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
14 Ose J, Botma A, Balavarca Y, Buck K, Scherer D, Habermann N, Beyerle J, Pfütze K, Seibold P, Kap EJ, Benner A, Jansen L, Butterbach K, Hoffmeister M, Brenner H, Ulrich A, Schneider M, Chang-Claude J, Burwinkel B, Ulrich CM. Pathway analysis of genetic variants in folate-mediated one-carbon metabolism-related genes and survival in a prospectively followed cohort of colorectal cancer patients. Cancer Med 2018. [PMID: 29845757 DOI: 10.1002/cam4.1407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
15 Campbell JM, Bateman E, Peters MD, Bowen JM, Keefe DM, Stephenson MD. Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics 2016;17:435-51. [DOI: 10.2217/pgs.15.180] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
16 Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9-22. [PMID: 27569869 DOI: 10.1016/j.ctrv.2016.08.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
17 Liu Y, Wu H, Ye H, Chen Z, Song Q, Zou B, Rui J, Zhou G. A simplified pyrosequencing protocol based on linear-after-the-exponential (LATE)-PCR using whole blood as the starting material directly. Anal Methods 2014;6:1384-90. [DOI: 10.1039/c3ay41471j] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
18 Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011;12:1321-36. [PMID: 21919607 DOI: 10.2217/pgs.11.72] [Cited by in Crossref: 136] [Cited by in F6Publishing: 117] [Article Influence: 13.6] [Reference Citation Analysis]
19 Ulrich CM, Rankin C, Toriola AT, Makar KW, Altug-Teber Ö, Benedetti JK, Holmes RS, Smalley SR, Blanke CD, Lenz HJ. Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304). Cancer 2014;120:3329-37. [PMID: 25041994 DOI: 10.1002/cncr.28830] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
20 Pucket JD, Gilmour MA. Intralesional 5-fluorouracil (5-FU) for the treatment of eyelid squamous cell carcinoma in 5 horses: Intralesional 5-FU for treatment of equine eyelid squamous cell carcinoma. Equine Veterinary Education 2014;26:331-5. [DOI: 10.1111/j.2042-3292.2011.00259.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Berardi R, Maccaroni E, Onofri A, Morgese F, Torniai M, Tiberi M, Ferrini C, Cascinu S. Locally advanced rectal cancer: The importance of a multidisciplinary approach. World J Gastroenterol 2014; 20(46): 17279-17287 [PMID: 25516638 DOI: 10.3748/wjg.v20.i46.17279] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
22 Xie B, Becker E, Stuparevic I, Wery M, Szachnowski U, Morillon A, Primig M. The anti-cancer drug 5-fluorouracil affects cell cycle regulators and potential regulatory long non-coding RNAs in yeast. RNA Biol 2019;16:727-41. [PMID: 30760080 DOI: 10.1080/15476286.2019.1581596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol 2014; 20(29): 9775-9827 [PMID: 25110414 DOI: 10.3748/wjg.v20.i29.9775] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 75] [Article Influence: 9.3] [Reference Citation Analysis]
24 Esposito D, Crescenzi E, Sagar V, Loreni F, Russo A, Russo G. Human rpL3 plays a crucial role in cell response to nucleolar stress induced by 5-FU and L-OHP. Oncotarget 2014;5:11737-51. [PMID: 25473889 DOI: 10.18632/oncotarget.2591] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
25 Kotake M, Bando H, Kaneko M, Takemura H, Minamoto T, Kawakami K. Thymidylate synthase locus LOH in combination with genotype has prognostic and predictive significance in colorectal cancer. Mol Clin Oncol 2021;15:235. [PMID: 34650802 DOI: 10.3892/mco.2021.2398] [Reference Citation Analysis]
26 Luo D, Zhang Y, Yang S, Tian X, Lv Y, Guo Z, Liu X, Han G, Liu S, Wang W, Cui S, Qu X, Wan S. Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer. Eur J Med Chem 2021;225:113775. [PMID: 34411894 DOI: 10.1016/j.ejmech.2021.113775] [Reference Citation Analysis]
27 Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther 2020;206:107447. [PMID: 31756363 DOI: 10.1016/j.pharmthera.2019.107447] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 24.3] [Reference Citation Analysis]
28 Galbiatti AL, Caldas HC, Maniglia JV, Pavarino EC, Goloni-Bertollo EM. Gene expression profile of 5-fluorouracil metabolic enzymes in laryngeal cancer cell line: predictive parameters for response to 5-fluorouracil-based chemotherapy. Biomed Pharmacother 2014;68:515-9. [PMID: 24751000 DOI: 10.1016/j.biopha.2014.03.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
29 Matuskova M, Baranovicova L, Kozovska Z, Durinikova E, Pastorakova A, Hunakova L, Waczulikova I, Nencka R, Kucerova L. Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells: MSC-mediated gene therapy depends on tumour cells properties. J Gene Med 2012;14:776-87. [DOI: 10.1002/jgm.2684] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
30 Brunn ND, Dibrov SM, Kao MB, Ghassemian M, Hermann T. Analysis of mRNA recognition by human thymidylate synthase. Biosci Rep 2014;34:e00168. [PMID: 25423174 DOI: 10.1042/BSR20140137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
31 Brunn ND, Garcia Sega E, Kao MB, Hermann T. Targeting a regulatory element in human thymidylate synthase mRNA. Chembiochem 2012;13:2738-44. [PMID: 23143777 DOI: 10.1002/cbic.201200603] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
32 Wang WB, Yang Y, Zhao YP, Zhang TP, Liao Q, Shu H. Recent studies of 5-fluorouracil resistance in pancreatic cancer. World J Gastroenterol 2014; 20(42): 15682-15690 [PMID: 25400452 DOI: 10.3748/wjg.v20.i42.15682] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
33 Park JB, Lee JS, Lee MS, Cha EY, Kim S, Sul JY. Corosolic acid reduces 5‑FU chemoresistance in human gastric cancer cells by activating AMPK. Mol Med Rep 2018;18:2880-8. [PMID: 30015846 DOI: 10.3892/mmr.2018.9244] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
34 Kucerova L, Feketeova L, Kozovska Z, Poturnajova M, Matuskova M, Nencka R, Babal P. In vivo 5FU-exposed human medullary thyroid carcinoma cells contain a chemoresistant CD133+ tumor-initiating cell subset. Thyroid 2014;24:520-32. [PMID: 24073856 DOI: 10.1089/thy.2013.0277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
35 Moodley T, Singh M. Polymeric Mesoporous Silica Nanoparticles for Enhanced Delivery of 5-Fluorouracil In Vitro. Pharmaceutics 2019;11:E288. [PMID: 31248179 DOI: 10.3390/pharmaceutics11060288] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 9.7] [Reference Citation Analysis]
36 Giampieri R, Restivo A, Pusceddu V, Del Prete M, Maccaroni E, Bittoni A, Faloppi L, Andrikou K, Bianconi M, Cabras F, Berardi R, Zorcolo L, Scintu F, Cascinu S, Scartozzi M. The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. Clinical Colorectal Cancer 2017;16:38-43. [DOI: 10.1016/j.clcc.2016.07.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
37 Ke W, Saba JA, Yao CH, Hilzendeger MA, Drangowska-Way A, Joshi C, Mony VK, Benjamin SB, Zhang S, Locasale J, Patti GJ, Lewis N, O'Rourke EJ. Dietary serine-microbiota interaction enhances chemotherapeutic toxicity without altering drug conversion. Nat Commun 2020;11:2587. [PMID: 32444616 DOI: 10.1038/s41467-020-16220-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]